Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision: v3.5.0 deployed.SummaryDifference0.0%

- Check16 days agoChange Detected- Revision updated from v3.4.2 to v3.4.3; no user-visible changes to the study page.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check45 days agoChange DetectedA minor page revision was applied, moving from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check52 days agoChange DetectedOnly a page revision update from v3.4.0 to v3.4.1 is visible; no core content or study data changes were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check59 days agoChange DetectedUI and metadata elements were updated, including a visible 'Show glossary' label and capitalization adjustments to the QC-related update text. A site revision banner now shows v3.4.0, replacing the previous v3.3.4.SummaryDifference0.1%

- Check74 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no substantive changes to study data, eligibility, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.